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Abstract. 
 
Glutathione depletion occurs in several 
forms of apoptosis and is associated with Parkinson’s 
disease and HIV toxicity. The neurotransmitter 
glutamate kills immature cortical neurons and a hip-
pocampal nerve cell line via an oxidative pathway asso-
ciated with glutathione depletion. It is shown here that 
soluble guanylyl cyclase (sGC) activity is required for 
nerve cell death caused by glutathione depletion. Inhib-
itors of sGC block glutamate toxicity and a cGMP ana-
logue potentiates cell death. Glutamate also induces an 
elevation of cGMP that occurs late in the cell death 
pathway. The resultant cGMP modulates the increase 
in intracellular calcium that precedes cell death because 
sGC inhibitors prevent calcium elevation and the 
cGMP analogue potentiates the increase in intracellu-
lar calcium. These results suggest that the final pathway 
of glutamate induced nerve cell death is through a 
cGMP-modulated calcium channel.
 
G
 
lutathione
 
 is a cysteine-containing tripeptide (
 
g
 
-
glutamylcysteinylglycine) that exists in both the
reduced (GSH)
 
1
 
 and the oxidized states (GSSG).
GSH is the predominant form within the cell, usually ac-
counting for greater than 99% of the total glutathione
(Meister and Anderson, 1983). GSH plays an important
role in protecting cells from oxidative damage and regu-
lates several aspects of cellular metabolism. The synthesis
of GSH is regulated by the enzyme 
 
g
 
-glutamyl-cysteine
synthetase and its precursor molecule, cysteine, which is
present at low concentration within the cell. Low levels of
intracellular GSH are linked to a variety of pathological
conditions, such as HIV (Herzenberg et al., 1997) and Par-
kinson’s disease (Perry et al., 1982; Sofic et al., 1992; Sian
et al., 1994). This association appears to be significant be-
cause HIV-infected lymphocytes that contain decreased
intracellular GSH are more likely to undergo apoptosis
(Staal et al., 1992; Ameisen et al., 1995). Artificially elevat-
ing GSH by 
 
N
 
-acetylcysteine prolongs the survival of the
HIV-infected cells (Herzenberg et al., 1997). In the ner-
vous system, there is an early and highly specific decrease
in GSH in the substantia nigra of Parkinson’s disease pa-
tients (Perry et al., 1982; Sofic et al., 1992; Sian et al.,
1994), and the artificial depletion of GSH both induces
dopaminergic neuronal cell death in vitro (Jenner and Ol-
anow, 1996) and potentiates the toxicity of 6-hydroxy-
dopamine and 1-methyl-4-phenylpyridinium (MPP
 
1
 
)
 
 
 
in
vivo (Pileblad et al., 1989; Wullner et al., 1996). Together,
these data suggest that GSH depletion directly contributes
to cell death in a variety of cell types.
GSH depletion is observed in models of apoptotic cell
death, including glucocorticoid-induced thymocyte apop-
tosis (Beaver and Waring, 1995; Slater et al., 1995) and
anti-Fas/APO-1–induced T lymphocyte apoptosis (van den
Dobbelsteen et al., 1996). Several mechanisms account for
the depletion of GSH. (
 
a
 
) The production of reactive oxy-
gen species and the increased requirement for glutathione
peroxidase may lead to the consumption of GSH. (
 
b
 
) The
activation of a transmembrane export channel appears to
be responsible for the decline in intracellular GSH during
apoptosis in lymphocytes (van den Dobbelsteen et al.,
1996) and U937 human monocytic cells (Ghibelli et al., 1995).
(
 
c
 
) When persistently exposed to the neurotransmitter
glutamate, immature cortical neurons, which do not have
ionotropic glutamate receptors, are depleted of intracellu-
lar GSH through the competition by glutamate for cystine
uptake (Murphy and Baraban, 1990; Murphy et al., 1990).
Elevated levels of extracellular glutamate interfere with
the exchange of glutamate with cystine through a cystine/
glutamate antiporter, which normally carries cystine into
the cell. This leads to a decrease in the level of intracellu-
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1.
 
 Abbreviations used in this paper
 
:
 
 
 
BSO, buthionine sulfoximine; CPT-
cGMP, 8-(4-chlorophenylthio) guanosine-3
 
9
 
-5
 
9
 
-cyclic monophosphate;
GSH, reduced glutathione; GSSG, oxidized glutathione; LOX, lipoxygen-
ase; MTT, 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyl tetrazolium bromide;
NO, nitric oxide; NOS, nitric oxide synthase; PKG, cGMP-dependent pro-
tein kinase; sGC, soluble guanylyl cyclase.
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lar cystine and its reduction product cysteine, thereby
causing a decrease in the level of GSH. This mechanism,
called oxidative glutamate toxicity, has also been de-
scribed in a hippocampus nerve cell line HT22 (Davis and
Maher, 1994), in a nerve-glial hybrid cell line N18-RE-105
(Murphy et al., 1989), and in primary oligodendrocytes
(Oka et al., 1993). When artificially depleted of GSH, im-
mature cortical neurons also undergo programmed cell
death (Ratan et al., 1994).
The steps linking GSH depletion to neuronal cell death
are largely unknown. We have been studying this pathway
using glutamate treatment of immature cortical neurons
and a neuronal cell line. Recently, we found that depletion
of GSH activates neuronal 12-lipoxygenase (12-LOX), which
leads to the production of reactive oxygen species, the in-
crease in intracellular Ca
 
2
 
1
 
, and ultimately to cell death
(Li et al., 1997). The experiments outlined below extend
these studies to show that the soluble guanylyl cyclase (sGC)/
cGMP pathway is involved in nerve cell death caused by
GSH depletion. This investigation was predicated upon
the following observations. First, Ca
 
2
 
1
 
 elevation is re-
quired for oxidative glutamate-induced neuronal cell death
since the removal of extracellular Ca
 
2
 
1
 
 prevents cell death
(Murphy et al., 1989; Davis and Maher, 1994) and the in-
tracellular Ca
 
2
 
1
 
 level increases during cell death (Li et al.,
1997). One possible regulator of Ca
 
2
 
1
 
 elevation is cGMP
since cGMP can directly or indirectly modulate some ion
channels (Yau, 1994; Kaupp, 1995; Finn et al., 1996). Sec-
ond, LOX activation is required for glutamate toxicity (Li
et al., 1997), and LOX metabolites activate sGC (Snider et
al., 1984; Brune and Ulrich, 1991). This paper reports the
first evidence for a role of sGC in mediating programmed
cell death caused by glutathione depletion. 
 
Materials and Methods
 
Cell Cultures
 
Mouse hippocampal HT22 cells (Davis and Maher, 1994) are derived from
the HT4 cell line (Morimoto and Koshland, 1989) and are propagated in
DME (Vogt and Dulbecco, 1963) supplemented with 10% FBS. Primary
cortical neurons were prepared from embryonic day 17 Sprague-Dawley
rats as described (Abe et al., 1990). After dissociation from brain tissues
with trypsin and DNase I, cells were maintained in MEM supplemented
with 30 mM glucose, 2 mM glutamine, 1 mM pyruvate, and 10% FBS.
 
Cell Viability Assay
 
Cell viability was determined by either visual cell counting or MTT assays
in 96-well plates. The MTT assays measure the ability of cells to metabo-
lize 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
and is often used to measure cellular proliferation (Mosmann, 1983). In
this system, it correlates with cell viability as determined by trypan blue
exclusion and a colony-forming assay (Davis and Maher, 1994). The assay
medium contained 5% dialyzed FBS for the glutamate toxicity assay or
horse serum for the assay of buthionine sulfoximine (BSO) toxicity (Li et
al., 1997). Fresh preparations of BSO were used. For the MTT assay, cells
were dissociated and seeded into 96-well microtiter plates at a density of
2.5 
 
3
 
 10
 
3 
 
or 5 
 
3 
 
10
 
4 
 
cells per well in 100 
 
m
 
l medium for HT22 cells and cor-
tical neurons, respectively. The next day cells were treated with various
reagents according to the experimental design. 20 h after the treatment,
10 
 
m
 
l of MTT solution (5 mg/ml) was added to each well and incubated for
3 h. 100 
 
m
 
l of solubilization solution (50% dimethylformamide, 20% SDS,
pH 4.8) was then added to the wells, and the next day the absorption value
at 570 nm was measured. Results are expressed relative to the indicated
controls and were analyzed using a Mann-Whitney test.
 
Glutathione, cGMP, and Ca
 
2
 
1
 
 Measurements
 
For the glutathione, cGMP, and Ca
 
2
 
1
 
 measurements to be described be-
low, HT22 cells were seeded at 5 
 
3 
 
10
 
5
 
 cells/100 mm and the next day
were treated according to the experimental design. Cells were then col-
lected at indicated times for the above assays. Glutathione was deter-
mined by the recycling assay based on the reduction of 5,5-dithiobis(2-
nitrobenzoic acid) with glutathione reductase and NADPH (Tietze, 1969).
Sample preparation and assay procedures were described elsewhere (Li et
al., 1997).
 For cGMP determination, HT22 cells were treated with glutamate for
various times, collected, and resuspended in 0.1
 
 
 
N HCl. After 1 h on ice,
the samples were centrifuged in a microfuge. The supernatant was neu-
tralized and assayed for cGMP content using an EIA cGMP assay kit from
Amersham International (Buckinghamshire, England). The pellet was
dissolved in 0.1
 
 
 
N NaOH, and protein content was determined using a
commercial kit from Pierce Chemical Co. (Rockford, IL). cGMP content
was calculated per milligram protein and presented relative to the con-
trols. 
 The intracellular ionized calcium concentration was determined by
flow cytometry using ratiometric analysis. HT22 cells were loaded with 1 
 
m
 
M
Indo-1 at 37
 
8
 
C for 30 min in the presence of 0.005% Pluronic F-127 in
DME containing 10% FCS. After incubation, cells were collected,
washed, and resuspended in phenol red–free Hepes-buffered DME sup-
plemented with 2% dialyzed FBS. Cells were allowed a 15-min recovery
period to hydrolyze the ester bond before being analyzed with a FACStar-
plus
 
®
 
 flow cytometer (Becton Dickinson, Mountain View, CA). The fluo-
rescence light from the two emission peaks of Indo-1, 410 nm (violet) and
485 nm (green), was collected, and the ratio of violet to green, which is
proportional to Ca
 
2
 
1
 
 
 
concentrations
 
 
 
(Grynkiewicz et al., 1985), was ob-
tained. 10,000 viable cells were analyzed in each assay. 
 
Reagents
 
Tissue culture reagents were obtained from GIBCO BRL (Gaithersburg,
MD). The fluorescent dye Indo-1 acetoxymethylester was obtained from
Molecular Probes (Eugene, OR). LY83583, N
 
G
 
-methyl-
 
l
 
-arginine, nife-
dipine, N
 
G
 
-nitro-
 
l
 
-arginine, 7-nitroindazole, and tin protophorphorin IX
were from LC Laboratories (Woburn, MA). 8-(4-chlorophenylthio) gua-
nosine-3
 
9
 
-5
 
9
 
-cyclic monophosphate (CPT-cGMP) was obtained from Biolog
(La Jolla, CA). Other reagents, including 
 
l
 
, 
 
d
 
-buthionine sulfoximine, hy-
droxylamine, methylene blue, 
 
N
 
-methyl-hydroxylamine, and N
 
G
 
-monom-
ethyl-
 
l
 
-arginine methyl ester, were purchased from Sigma Chemical Co.
(St. Louis, MO).
 
Results
 
Inhibitors of sGC Prevent Glutamate-induced Neuronal 
Cell Death
 
The addition of glutamate to the hippocampal cell line
HT22 causes a rapid depletion of GSH, which in turn acti-
vates 12-LOX, leading to a form of programmed cell death
that is similar to but distinct from apoptosis (Tan, S., M.
Wood, and P. Maher, manuscript submitted for publica-
tion). It has recently been shown that the products of
12-LOX enzymatic activity are required for oxidative
glutamate toxicity (Li et al., 1997). One target for LOX
metabolites is sGC (Snider et al., 1984; Brune and Ulrich,
1991). To determine if sGC is involved in glutamate toxic-
ity, we first tested the effect of various inhibitors of sGC
on the survival of HT22 cells after exposure to glutamate.
HT22 cells were incubated with 5 mM glutamate in the
presence of several concentrations of the inhibitors for 20 h.
Cell viability was then determined by MTT reduction, a vi-
ability assay that correlates in this system with trypan blue
exclusion and colony formation assays (Davis and Maher,
1994). Under these conditions, glutamate alone caused the
complete lysis of cells as assayed by both MTT reduction
(Fig. 1 
 
A
 
) and microscopic examination. Treatment of the 
Li et al. 
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cells with 6-anillino-5,8-quinolinedione (LY83583), a spe-
cific inhibitor of sGC (Mulsch et al., 1988), inhibited the
toxicity of glutamate in a concentration-dependent man-
ner (Fig. 1 
 
A
 
 and data not shown). The IC
 
50
 
 for the inhibi-
tion of glutamate toxicity was 0.5 
 
m
 
M, which is in good
agreement with the concentration of LY83583 required
for sGC inhibition in isolated tissues (Mulsch et al., 1988).
Inhibitors with very different structures from LY83583, in-
cluding methylene blue (Gruetter et al., 1981), hydroxy-
lamine, and 
 
N
 
-methyl-hydroxylamine (Deguchi et al., 1978),
all inhibited glutamate-induced cell death in a dose-depen-
dent manner (Fig. 1 
 
A
 
 and data not shown). The concentra-
tions giving the maximal protection were all in the ranges
that inhibit the activation of the purified sGC and/or block
cGMP elevation in isolated tissues (Deguchi et al., 1978;
Gruetter et al., 1981). Although these structurally unre-
lated inhibitors may have other effects on cells, their only
shared target is sGC.
To determine whether the above observations with
HT22 cells reflect the mechanism of oxidative glutamate
toxicity on central nervous system cells, embryonic rat cor-
tical neurons were prepared, and 1 d later the cells were
exposed to glutamate as with HT22 cells. These young cul-
tures are devoid of functional glutamate receptors and are
killed by nonreceptor-mediated glutamate-induced oxida-
tive stress (Murphy and Baraban, 1990; Murphy et al.,
1990). Fig. 1 
 
B
 
 shows that the sGC inhibitors LY83583,
methylene blue, and 
 
N
 
-methyl-hydroxylamine also block
glutamate toxicity in primary neuronal cell cultures. These
results are identical to those obtained with HT22 cells, ex-
cept that the optimal concentrations of the inhibitors are
lower. Hydroxylamine itself was toxic to primary cortical
neurons, which is probably because hydroxylamine gives
rise to nitric oxide (NO). Several other NO-releasing com-
pounds induce apoptosis in cortical neurons (Palluy and
Rigaud, 1996). The above results suggest that sGC is a crit-
ical enzyme in oxidative glutamate toxicity.
 
Inhibitors of sGC Also Prevent Neuronal Cell Death 
Induced by Buthionine Sulfoximine
 
Since the activation of 12-LOX has been experimentally
linked to the reduced level of intracellular GSH (Li et al.,
1997), it was asked if GSH depletion is also sufficient to
activate sGC-mediated cell death. To determine if sGC is
also involved in neuronal cell death associated with GSH
depletion, the effect of sGC inhibitors on BSO toxicity was
examined. BSO, a specific inhibitor of 
 
g
 
-glutamylcysteine
synthetase, the rate-limiting enzyme in GSH synthesis,
depletes intracellular GSH and causes cell death in a time-
and dose-dependent manner in both HT22 cells and pri-
mary cortical neurons (Li et al., 1997). An overnight expo-
sure of HT22 cells or primary cortical neurons to 50 
 
m
 
M
BSO causes glutathione depletion (Fig. 2) and a dramatic loss
of cell viability (Fig. 1, 
 
C
 
 and 
 
D
 
). sGC inhibitors LY83583,
methylene blue, and 
 
N
 
-methyl-hydroxylamine all block BSO
toxicity in a manner similar to that of glutamate, suggesting
that sGC is directly linked to neuronal cell death caused
by GSH depletion. There are, however, differences in the
pharmacology of sGC inhibitors that prevent glutamate-
and BSO-induced cell death. These differences may be
due to the fact that at least the early events are different
for these two models of cell death, because glutamate in-
terferes with the cystine uptake while BSO directly inhib-
its GSH synthesis.
 
sGC Inhibitors Do Not Affect the Ability of Glutamate 
or BSO to Deplete GSH
 
To determine whether sGC inhibitors block the toxicity of
glutamate and BSO by affecting their ability to deplete
GSH, we compared intracellular glutathione levels in HT22
cells treated with these agents as a function of time. Fig. 2
shows that sGC inhibitor LY83583 did not block the de-
pletion of GSH by either glutamate or BSO. None of the
other sGC inhibitors blocked glutathione depletion either
(data not shown). In the case of BSO treatment, the addi-
tion of LY83583 accelerated the depletion of GSH (Fig.
Figure 1. sGC inhibitors prevent nerve cell death caused by
glutamate and BSO. Experiments were performed as described
in the Materials and Methods. Results are expressed as relative to
controls treated with agents alone. The results shown are the
mean 6 SD of a typical experiment with five determinations.
*Significantly different from glutamate treatment (P , 0.01,
Mann-Whitney test). Similar results were obtained in three inde-
pendent experiments. (A) Dose effect of sGC inhibitors and NOS
inhibitor NG-monomethyl-l-arginine methyl ester (NAME) on
glutamate toxicity in HT22 cells. LY, LY83583; MB, methylene
blue; NMH, N-methyl-hydroxylamine; HA, hydroxylamine. The
concentrations given above each compound are in micromolar.
The glutamate concentration used was 5 mM. Note that more
than five doses were tested but only the optimum and a lower
dose were presented. (B) Dose effect of sGC inhibitors and
NAME on glutamate toxicity in rat cortical neurons. (C) Dose ef-
fect of sGC inhibitors and NAME on BSO toxicity in HT22 cells.
BSO was added to the growth medium at 50 mM. (D) Dose effect
of sGC inhibitors and NAME on BSO toxicity in rat cortical neu-
rons. 
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2). This is probably due to the fact that LY83583 is also ca-
pable of inhibiting glutathione reductase (Luond et al.,
1993) and therefore the regeneration of GSH from GSSG.
These data, showing that sGC inhibitors prevent cell death
but not GSH depletion, support the previous argument
that GSH depletion caused by glutamate is not in itself
sufficient to cause cell lysis (Murphy et al., 1989).
 
The Activation of sGC Occurs Near the Time of
Cell Death
 
Since sGC inhibitors block toxicity, it is likely that the en-
zyme is activated to produce cGMP. To determine if there
is an increase in the level of cGMP, intracellular cGMP
levels of HT22 cells treated with 5 mM glutamate for various
times were assayed. Fig. 3 
 
A
 
 shows that the level of cGMP
starts to increase 8 h after glutamate treatment. Under the
conditions used, cells also begin to die at 
 
z
 
8 h after the ad-
dition of glutamate. The increase in cGMP was prevented
by treatment of cells with 1 
 
m
 
M LY83583 (data not shown).
Therefore, sGC activation occurs near the time of cell death.
To independently determine when in the cytotoxicity
pathway sGC is activated, HT22 cells were treated with
glutamate, and at various times afterwards LY83583 was
added, followed by a cell viability assay at 20 h. Alterna-
tively, glutamate was added and then removed at various
times after its initial addition to the cultures. LY83583 was
able to inhibit glutamate toxicity even when applied up to
8 h into the cell death process (Fig. 3 
 
B
 
). The protection
conferred by LY83583 started declining at 8 h after addi-
tion of glutamate, which is the same time that glutamate
was no longer required for cell death (Fig. 3 
 
B
 
). After 
 
z
 
8
h of exposure to glutamate, HT22 cells gradually initiate
cell lysis, which is complete after 
 
z
 
15 h. However, surviv-
ing cells can still be rescued by LY83583 even during the
late period of cell death. For example, if 1 
 
m
 
M LY83583 is
added to cultures when 73% of cells are dead, the remain-
ing 27% of the cells survive when examined 24 h later.
These observations suggest that the activation of sGC oc-
curs at a point that is very close to cell lysis.
 
A Cell-permeable cGMP Analogue Potentiates 
Glutamate Toxicity
 
If cGMP is involved in the cell death pathway, then exoge-
nous cGMP should potentiate glutamate toxicity. The ability
of CPT-cGMP, a cell permeable and phosphodiesterase-
resistant cGMP analogue, to potentiate glutamate-induced
cell death was examined. Overnight exposure of HT22
cells to 2 mM glutamate led to a 35% decrease in cell via-
bility (Fig. 4 
 
A
 
). Coapplication of CPT-cGMP resulted in
further decreases in cell viability in a dose-dependent man-
ner. For example, 2 mM glutamate caused a 35% cell death,
while 500 
 
m
 
M CPT-cGMP together with 2 mM glutamate
caused nearly a 90% decrease in cell viability (Fig. 4 
 
A
 
).
At 500 
 
m
 
M, CPT-cGMP alone was not significantly toxic
to HT22 cells. However, marked cell death was observed
when these cells were treated with CPT-cGMP at concen-
trations over 1 mM (Fig. 4 
 
A
 
, 
 
inset
 
). Application of the less
stable cGMP analogues, dibutyl-cGMP and 8-bromo-cGMP,
did not result in cell death at concentrations up to 5 mM.
The potentiation by CPT-cGMP was dependent on gluta-
mate concentration (Fig. 4 
 
B
 
) but was largely unaffected
by the time when CPT-cGMP was added up to 12 h after
glutamate addition (Fig. 4 
 
C
 
). This result is consistent with
the above data, suggesting that cGMP functions near the
time when cells die.
 
cGMP-dependent Protein Kinase Is Not Involved in 
Glutamate Toxicity
 
Since the molecular targets of cGMP action include cGMP-
gated ion channels and cGMP-dependent protein kinases
(PKG) and phosphodiesterases (Goy, 1991), it is expected
Figure 2. sGC inhibitor
LY83583 does not prevent
the depletion of glutathione
by glutamate or BSO. HT22
cells were treated with either
5 mM glutamate or 50 mM
BSO in the presence or ab-
sence of 2 mM LY83583 for
various times. The cells were
collected and assayed for glu-
tathione levels and protein
content. The data are pre-
sented relative to controls (0
h, no treatment). The level of glutathione was 12.4 6 0.62 nmol/mg
protein and 8.08 6 0.08 nmol/mg protein for cells grown in FCS-
containing medium and horse serum–containing medium, re-
spectively. Horse serum was used when BSO toxicity was studied
because it gave more sensitive and consistent results (Li et al., 1997).
Figure 3. Glutamate induces
the increased production of
cGMP. (A) Time course
analysis of cGMP produc-
tion. HT22 cells were treated
with 5 mM glutamate for var-
ious times, collected, and as-
sayed for cGMP and protein
levels. Data are presented
relative to controls. The
cGMP level for control cells
is 190 6 23 fmol/mg protein.
Similar results were obtained
in two independent experi-
ments, each with multiple
samples. (B) The ability of
various reagents to block
glutamate toxicity as a func-
tion of time when they are
added to medium. HT22 cells
were treated with 5 mM
glutamate, and at various
times after the addition, re-
agents were added to the me-
dium and cell viability was
assayed next day. Cell viabil-
ity is presented relative to controls without any treatment.
Glutamate, 5 mM; LY83583, 2 mM; CoCl2, 50 mM; 2Glu, re-
placement with normal DME. Similar results were obtained in
two independent experiments. Note that cell viability was com-
pared with untreated controls 20 h after the initial seeding. HT22
cells have a short doubling time and grow to nearly four times the
original cell number in 20 h. The apparent initial low viabilities
conferred by the protectants reflect a lower rate of proliferation
rather than survival.Li et al. cGMP Mediates Nerve Cell Death 1321
that the inhibition of sGC will affect the activity of these
targets. If they are in the cell death pathway, then their in-
hibition will also block cell death. We examined whether
PKG is involved in cell death using KT5823, a highly selec-
tive inhibitor of PKG with an IC50 of 0.23 mM (Ito and
Karachot, 1990). Fig. 4 D shows that KT5823 was unable
to block cell death even at concentration up to 100 mM,
suggesting that PKG is not involved in the cell death
caused by GSH depletion.
sGC/cGMP Regulates the Elevation of Ca21
Another potential target for cGMP is the activation of
Ca21 channels, which play an important role in oxidative
glutamate toxicity. The removal of extracellular Ca21 or
the addition of the Ca21 channel blocker CoCl2 inhibits
glutamate toxicity (Murphy et al., 1989; Davis and Maher,
1994), and glutamate induces the elevation of intracellular
Ca21 (Li et al., 1997). These data suggest that the increased
intracellular Ca21 is derived from extracellular medium
rather than intracellular calcium pools. Initial experiments
were done to identify the specific channels involved in cell
death. The influx of Ca21 may be via voltage-dependent
channels, cGMP-regulated channels, Na1/Ca21 exchang-
ers, or nonspecific membrane leakage. Membrane leakage
is unlikely since CoCl2 prevents cell death (Murphy et al.,
1989; Davis and Maher, 1994). Replacement of Na1 by Li1
did not prevent cell death (data not shown), which ex-
cludes the involvement of a Na1/Ca21 exchanger. Various
inhibitors of Ca21 channels were then tested for their abil-
ity to prevent cell death induced by glutamate. These in-
cluded the L-type channel inhibitors nifedipine, dilitizam,
verapamil, and nimodipine, and the N-type channel inhibi-
tor v-conotoxin GVIA. None of these was protective at
concentrations up to toxic doses (data not shown). There-
fore, it is unlikely that L- or N-type channels or Na1/Ca21
exchangers are involved in the cell death. The involvement
of a cGMP-regulated Ca21 channel can not be tested bio-
chemically because no specific inhibitors exist (Finn et al.,
1996). Although pimozide and D600 can block these chan-
nels in some cases (Finn et al., 1996), they were not effec-
tive in preventing cell death caused by glutathione deple-
tion (data not shown). If, however, it were possible to
demonstrate that CPT-cGMP potentiates the increase in
intracellular Ca21 in a manner similar to toxicity, then it is
likely that cGMP-gated Ca21 channels are opened. Fig. 5 A
shows that CPT-cGMP indeed potentiates Ca21 elevation.
CPT-cGMP greatly enhances the level of intracellular
Ca21 in cells exposed to marginally toxic (2 mM) concen-
trations of glutamate.
It was then asked if there is a temporal relationship be-
tween sGC activation and Ca21 elevation. Cells were ex-
posed to LY83583 and CoCl2 at various times after the ad-
dition of glutamate, and cell viability was assayed 20 h
after the initial addition of glutamate. Fig. 3 B shows that
LY83583 and CoCl2 function in parallel in terms of maxi-
mal protection. Both agents maintain maximal protection
up to 8 h past the addition of glutamate, after which cell ly-
sis occurs gradually over the next few hours. Therefore,
both sGC activation and Ca21 elevation occur near the
time of cell death. 
If sGC activation is required for Ca21 elevation, then its
inhibition should block the glutamate-induced accumula-
tion of intracellular Ca21. We therefore investigated the
effect of sGC inhibitors on the intracellular Ca21 profile
during the glutamate treatment. The intracellular Ca21 re-
sponse to glutamate was first determined by flow cytome-
try using ratiometric analysis. Intracellular Ca21 content is
proportional to the ratio of fluorescence intensities from
the two emission peaks of the Ca21-bound and unbound
Indo-1 dye (Grynkiewicz et al., 1985) and was arbitrarily
defined as low (the ratio is less than 50), medium (the ratio
is between 50 and 100), and high (the ratio is between 100
and 250). In control cells, only about 2% of the cells had
medium to high levels of Ca21, with very few cells contain-
ing the high Ca21 level (Fig. 5 B; percentiles of cells in
each class were derived from the scatter plots shown).
Treatment with 5 mM glutamate for 12 h resulted in a dra-
Figure 4. The cell-permeable cGMP analogue CPT-cGMP po-
tentiates glutamate-induced cell death. (A and B) Dose effect of
CPT-cGMP and glutamate on cell viability. HT22 cells were
treated overnight with glutamate and/or CPT-cGMP at various
concentrations, and viability was determined by the MTT assay.
Results, presented relative to controls without any treatment, are
the mean 6 SD of a typical experiment with three determina-
tions. Similar results were obtained in three independent experi-
ments. (A, inset) Dose effect of CPT-cGMP on cell viability.
HT22 cells were treated for 20 h with CPT-cGMP at various con-
centrations, and viability was determined. Results are presented
relative to untreated controls. (C) A time course of the potentia-
tion effect afforded by CPT-cGMP. Cells were treated with 2 mM
glutamate, and at various times after the addition, 500 mM CPT-
cGMP was added. 24 h after the addition of glutamate, cell viabil-
ity was assayed. Similar results were obtained in three indepen-
dent experiments, each with three determinations. (D) A specific
inhibitor of protein kinase G, KT5823, does not prevent or atten-
uate cell death induced by glutamate. Experiments were per-
formed as described in the legend to Fig. 1.The Journal of Cell Biology, Volume 139, 1997 1322
matic increase in the percentages of cells containing me-
dium to high levels of Ca21 (Fig. 5 B). 12 h after the expo-
sure of cells to glutamate, z20% of the cells were alive. Of
these, only 10–20% had medium to high levels of Ca21
(Fig. 5 B and data not shown). The fact that the high Ca21–
containing cells accounted for such a minority of cells at
the time when cells were dying rapidly again suggests that
Ca21 elevation occurs very close to cell lysis. The rise of
Ca21 level during the incubation of cells with glutamate
was prevented by sGC inhibitors, while these inhibitors
had no effect on control cells (Fig. 5 B and data not
shown). Therefore, sGC inhibitors block glutamate-induced
Ca21 elevation in HT22 hippocampal cells. It was not,
however, possible to do these experiments in primary cul-
tures because of unstable baselines due to spontaneous
cell death in the short term cultures. 
sGC-mediated Glutamate Toxicity Is through a 
Mechanism Independent of NO and Carbon Monoxide
Since several of the inhibitors used above do not inhibit
the basal activity of sGC (see Discussion), the activation of
sGC is probably not due to its transcriptional upregula-
tion, but rather due to the induction of sGC activators. NO
and carbon monoxide are activators of sGC. If they are re-
sponsible for the sGC activation observed in the cell
death, these activators should also be a target for blocking
glutamate toxicity. Therefore, we determined if the inhibi-
tion of their synthesis is able to block glutamate toxicity. 
Various inhibitors of NO synthase (NOS) were tested at
several concentrations. NG-monomethyl-l-arginine methyl
ester, a specific inhibitor of NOS, did not attenuate gluta-
mate or BSO toxicity in HT22 cells or in primary cortical
neurons (Fig. 1). Other NOS inhibitors, including 7-nitro-
indazole (a specific inhibitor for neuronal NOS-1) (up to
0.25 mM), NG-methyl-l-arginine (up to 1.0 mM), and NG-
nitro-l-arginine (up to 1.0 mM), also did not show any
protective effect on glutamate toxicity (data not shown).
Similarly, tin protoporphyrin, an inhibitor of heme oxyge-
nase and carbon monoxide production, only had minimal
effects on glutamate toxicity at near toxic concentrations
(data not shown).
Discussion
The data presented above indicate a requirement for sGC/
cGMP in nerve cell death caused by GSH depletion. First,
three structurally unrelated inhibitors of sGC all block
glutamate or BSO toxicity (Fig. 1) at concentrations that
inhibit sGC activity or cause cGMP reduction in vitro. Sec-
ond, glutamate induces an increased production of cGMP
(Fig. 3). Third, a membrane-permeable cGMP analogue,
CPT-cGMP, potentiates glutamate toxicity (Fig. 4). Lastly,
sGC inhibitors block the glutamate-induced increase in in-
tracellular Ca21 required for toxicity (Fig. 5). Therefore,
the generation of cGMP and the subsequent activation of
a Ca21 channel are events occurring in GSH depletion–
induced nerve cell death.
Of the sGC inhibitors used here, hydroxylamine and its
analogue, N-methyl-hydroxylamine, competitively bind to
the heme group associated with sGC, inhibiting sGC acti-
Figure 5. sGC/cGMP regu-
lates the influx of Ca21. (A
and B) Representative scat-
ter plots depicting the violet/
green ratio of intracellular
Indo-1–emitted fluorescence
(proportional to Ca21) versus
the side angel scatter (SSC-
height, which is proportional
to the gravity of cells). HT22
cells were treated as indi-
cated for 12 h and Ca21 con-
tent determined as described
in Materials and Methods.
Each plot represents 10,000
viable cells. Similar results
were obtained in two inde-
pendent experiments with re-
peated samples. The level of
Ca21 was arbitrarily defined
as low (the violet/green ratio
less than 50), medium (the
ratio between 50 and 100),
and high (the ratio above
100), and the following per-
centages of cells containing
low, medium, and high Ca21
are given in that order. (A)
97.8, 2.0, and 0.2 (control):
91.5, 6.7, and 1.8 (2 mM Glu);
66.0, 22.0, and 12.0 (2 mM Glu 1 500 mM CPT-cGMP); and 96.9, 2.8, and 0.3 (500 mM CPT-cGMP). (B) 98.4, 1.5, and 0.1 (control); 90.2,
7.6, and 2.2 (5mM Glu); 98.9, 1.0, and 0.1 (5 mM Glu 1 1 mM LY83583); and 99.5, 0.5, and 0 (1 mM LY83583). Note that the baseline for
the control in A was higher than that in B.Li et al. cGMP Mediates Nerve Cell Death 1323
vation (Deguchi et al., 1978). However, the other sGC in-
hibitor, LY83583, appears to be relatively specific for sGC
in various studies (Schmidt et al., 1985; Mulsch et al.,
1988). The mechanism by which LY83583 inhibits sGC is
not completely known, but the inhibitory effect appears to
require the intracellular reduction of the compound
(Mulsch et al., 1988). However, LY83583 inhibits gluta-
thione reductase, thereby causing an increase in the level
of GSSG (Luond et al., 1993). This effect may contribute
to the ability of LY83583 to inhibit sGC since high levels
of GSSG can cause an irreversible loss of sGC activity
(Graff et al., 1978; Frey et al., 1980; Wu et al., 1992; Mayer
et al., 1995).
Both cytoprotective and cytotoxic roles for cGMP have
been described in the nervous system. For example, cGMP
prevents motor neuron degeneration (Weill and Greene,
1984) and protects against excitatory amino acid–induced
damage in cerebellar slices (Garthwaite and Garthwaite,
1988). cGMP may also be involved in the excitoprotective
activities of the secreted forms of b-amyloid precursor in
hippocampal neurons (Barger et al., 1995) and mediate
the survival effect of NO on trophic factor-deprived PC12
cells and sympathetic neurons (Farinelli et al., 1996). In
contrast, the accumulation of cGMP is associated with ret-
inal degeneration (Lolley et al., 1977; Bowes et al., 1990)
and possibly mediates excitatory amino acid–induced cy-
totoxicity in cortical neurons (Frandsen et al., 1992; Lustig
et al., 1992). The experiments presented above demon-
strate that sGC/cGMP is also a component in the cell
death pathway in nerve cells depleted of GSH.
It is likely that cGMP is responsible for the increase in
intracellular Ca21 required for glutamate toxicity. The ele-
vation of cGMP occurs late in the death pathway (Fig. 3),
and the increase in intracellular Ca21 also occurs late.
HT22 cells start to die z8 h after the addition of gluta-
mate, while sGC inhibitors are able to rescue cells even
when the majority of cells are dead, suggesting that sGC
activation occurs very shortly before actual cell death. The
elevation of Ca21, which was blocked by sGC inhibitors,
occurs only in 10–20% of cells at any time during the pe-
riod of disintegration (Fig. 5 B), suggesting that Ca21 accu-
mulation immediately precedes cell death in individual
cells. Additional evidence supporting the relevance of
Ca21 elevation with sGC/cGMP comes from the observa-
tions that: (a) CPT-cGMP potentiates the elevation of
Ca21 induced by glutamate (Fig. 5 A); (b) other potential
regulators of cGMP such as PKG (Fig. 4) and cGMP-regu-
lated phosphodiesterases are not involved in cell death;
and (c) inhibitors of the other classes of identified Ca21
channels are unable to prevent cell death. Therefore,
HT22 cells probably possess an unidentified cGMP-modu-
lated Ca21 channel (Finn et al., 1996).
Ca21 is known to be involved in programmed cell death
(McConkey and Orrenius, 1994). However, the regulator
and the effector molecule for these Ca21 fluxes are largely
unknown. Recently, it has been shown that Ca21 influx in
glucocorticoid-induced lymphocyte apoptosis is mediated
through the inositol 1,4,5-triphosphate receptor pathway
(Khan et al., 1996). It is therefore likely that various regu-
lators of Ca21 exist to control cell death in different envi-
ronments.
In summary, it is shown in a clonal cell line and primary
cortical neurons that the elevation of cGMP, which likely
results from sGC activation, is a critical step in the nerve
cell death caused by GSH depletion. The activation of sGC
is via an NO-independent mechanism. cGMP then induces
Ca21 influx, which immediately precedes cell death. If the
observation can be extended to in vivo situations, then in-
tervention of the sGC/cGMP pathway could be beneficial
to individuals suffering from PD or other pathologies asso-
ciated with GSH depletion.
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